
AnchorDx, a Chinese developer of DNA methylation NGS products, has raised $40 million in Series C financing. OrbiMed and WuXi Huiying Investment led the round.
Source: Press Release
AnchorDx, a Chinese developer of DNA methylation NGS products, has raised $40 million in Series C financing.
AnchorDx, a Chinese developer of DNA methylation NGS products, has raised $40 million in Series C financing. OrbiMed and WuXi Huiying Investment led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination